Subscribe to our mailings!

Thank You

Please choose your subscriptions:

Unsubscribe any time using the footer of our emails. For information about our privacy practices, please visit our privacy policy.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Financing & Capital Markets

A month into 2022 and all virtual “JPM meetings” completed, we took a moment to reflect on the past
An initial Public Offering has for decades been the endgame for an aspiring biotech company. Thinking back just 10 years, an IPO was conceivable generally only once a company had successfully brought at least one lead therapeutic into late-stage clinical trials and the pipeline was robust. Today this has changed...
Treehill Partners operates extensive Healthcare Investment Banking services and world class biotechnology Strategy Consulting as well as Leadership Support advisory services to some of today’s most innovative industry leadership teams. Over the years, as we evaluate investment proposals put forward to corporates, venture capitalists...
Many CEOs in biotechnology are focused on reaching out to as many investors as possible in a style that is known to be rather hectic and haphazard. A recent study showed that nearly 80% of institutional investors will not invest in a concept they do not understand scientifically. Saying it another way, if investors do not understand...
Proceeds will be used to fund Phase 2 ELAINE clinical trial, which is currently enrolling, to develop lasofoxifene as a potential precision medicine for metastatic breast cancer patients with ESR1 mutations. Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology...
Rising awareness and emergence of differentiated solutions for multiple psychiatric and mental health conditions is an ongoing theme of innovation in pharma but also adjacent and “convergence” fields in healthcare. Increasing incidence, certainly exacerbated by lockdowns and other measures implemented to curtail the spread of COVID-19, and the significant lack of innovation in the past represent the key ingredients for a resurgence, which is currently emerging.